Rudek, M A <br/><br/>
Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer.  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  Jan 2001 
 - 584-92 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, U.S. Gov't, P.H.S. 
<br/><br/><label>ISSN: </label>0732-183X 
<br/><br/><label>Standard No.: </label>10.1200/JCO.2001.19.2.584  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antineoplastic Agents--pharmacokinetics<br/>Endothelial Growth Factors--blood<br/>Enzyme Inhibitors--pharmacokinetics<br/>Female<br/>Fibroblast Growth Factor 2--blood<br/>Humans<br/>Lymphokines--blood<br/>Male<br/>Matrix Metalloproteinase 2--blood<br/>Matrix Metalloproteinase 9--blood<br/>Matrix Metalloproteinase Inhibitors<br/>Matrix Metalloproteinases--blood<br/>Middle Aged<br/>Neoplasms--drug therapy<br/>Statistics, Nonparametric<br/>Tetracyclines--pharmacokinetics<br/>Vascular Endothelial Growth Factor A<br/>Vascular Endothelial Growth Factors